Steven Chmura, MD, PhD
Enriched profileProfessor of Radiation and Cellular Oncology · University of Chicago Medical Center
Steven Chmura is Professor of Radiation and Cellular Oncology at University of Chicago Medical Center. OpenAlex indexes 344 publications with 10,257 citations (h-index 50); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Steven Chmura is Professor of Radiation and Cellular Oncology at University of Chicago Medical Center. The public record shows 344 publications with 10,257 citations (h-index 50), centered on Cancer Immunotherapy and Biomarkers, Advanced Radiotherapy Techniques, Breast Cancer Treatment Studies. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 9 companies, 2 NIH-funded awards (2014–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Cancer Immunotherapy and Biomarkers
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 9 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 124.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- Single vs Multi-fraction SRS Patients on Immunotherapy
Sponsor: University of Chicago
Industry payments
Updated 16 Oct 2026
9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SERVIER PHARMACEUTICALS LLCProgram year202514 payments$21,185openpaymentsdata.cms.gov ↗
- SERVIER PHARMACEUTICALS LLCProgram year202410 payments$20,264openpaymentsdata.cms.gov ↗
- RefleXion Medical, Inc.Program year20243 payments
NIH funding
Updated 16 Oct 2026
2 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
Congress activity
Updated 16 Oct 2026
65 congress contributions (2004–2024) across AACR, ASCO, ASTRO per OpenAlex. The most recent:
- Local and Marginal Failures in Spinal and Non-Spinal Osseous Metastases Receiving SBRT and Immunotherapy: A Secondary Analysis of Phase I Trials
ASTRO Annual Meeting
ASTRO2024Co-author - A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors.
ASCO Annual Meeting
ASCO2023Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer.
Journal of clinical oncology
Article2026 - Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function.
The Journal of experimental medicine
Article2026 - Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors.
Cancer research communications
Clinical Trial2025 - Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites.
Clinical cancer research
Article2024 - A multi-institutional phase I study of acetazolamide with temozolomide in adults with newly diagnosed MGMT-methylated malignant glioma.
Neuro-oncology advances
Article2024
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Improved survival time trends for glioblastoma using the SEER 17 population-based registriesArticle481 citations2011
- 04Stereotactic body radiotherapy for multisite extracranial oligometastasesArticle320 citations2011
- 05MicroRNA Expression Characterizes Oligometastasis(es)Article281 citations2011
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/steven-chmura-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Residency in Radiation Oncology
University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
2004provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uchicagomedicine.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uchicagomedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗
Editorial & leadership roles
journal and society appointments- Breast Liaison
NRG Oncology Radiation Oncology Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nrgoncology.org ↗ - Scientific Director
Cancer Clinical Trials Office, University of Chicago Comprehensive Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.uchicago.edu ↗
Secondary affiliations
appointments beyond the home institution- Department of Radiation and Cellular Oncology
University of Chicago
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Elaine Worcester
University of Chicago Medical Center
Luca Vricella
University of Chicago Medical Center
Adil Javed
University of Chicago Medical Center
Ahmet Atik, MD
University of Chicago Medical Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Hope Rugo, MD
City of Hope
Dennis Slamon, MD
University of California, Los Angeles